Sign In
Buy NVO
$49.28
-0.200 (-0.404%)
At Close: Jul 13, 2026
How To Build A $50,000 Dividend Portfolio In Today's Market
01:45pm, Monday, 13'th Jul 2026
The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize
NVO DCF Analysis: Intrinsic Value $90 vs Price $49
07:26am, Monday, 13'th Jul 2026
On July 13, 2026, we delve into the DCF analysis for Novo Nordisk AS (NVO), a company that has experienced notable price fluctuations recently. Over the past ye
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026
09:15am, Saturday, 11'th Jul 2026
Novo Nordisk is helping lead the way in the GLP-1 weight-loss niche. Realty Income is a real estate giant built to pay reliable dividends.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
08:00am, Saturday, 11'th Jul 2026
Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech comp
NVO Rallies 11% in a Month: How Should Investors Play the Stock?
11:16am, Friday, 10'th Jul 2026
Novo Nordisk stock gains 11% in a month as Wegovy access expands and U.K. approval boosts optimism, but rising competition and earnings pressure cloud the outlook.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
10:01am, Friday, 10'th Jul 2026
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
08:46am, Thursday, 09'th Jul 2026
Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly. NVO's Wegovy pill outpaces Eli Lilly's Fo
3 High Growth GLP-1 Biotech Winners to Buy in July
08:00am, Thursday, 09'th Jul 2026
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set.
Novo Nordisk: Why I Don't Think The Story Is Broken
07:52am, Thursday, 09'th Jul 2026
Novo Nordisk remains a Buy, supported by favorable catalysts and a resilient long-term bull case. NVO has surged 41% since my previous coverage, outperforming the benchmark's 18% return. Despite a rec
Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises
02:23am, Thursday, 09'th Jul 2026
Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, where diabetes rates are among the highest in the world.
Novo Nordisk (NVO) Dips More Than Broader Market: What You Should Know
06:46pm, Wednesday, 08'th Jul 2026
Novo Nordisk (NVO) reached $48.89 at the closing of the latest trading day, reflecting a -1.51% change compared to its last close.
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
11:34am, Wednesday, 08'th Jul 2026
Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy...
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdown
10:39am, Wednesday, 08'th Jul 2026
Shares in Novo Nordisk (NYSE:NVO) fell 2.5% to DKK319.20 after Deutsche Bank pointed to a continued slowdown in the oral version of the company's Wegovy weight-loss drug in the US. The bank published
Leading bank backs European pharma as the cleaner alternative to the AI trade
08:08am, Wednesday, 08'th Jul 2026
UBS has reiterated its overweight stance on European pharmaceuticals, framing the sector as a more resilient home for capital than artificial intelligence at a point when the wider market is slowing.
3 Reasons to Buy Novo Nordisk Stock
04:00pm, Tuesday, 07'th Jul 2026
The stock is down, but it isn't out yet.
